Physician profile
Felix Geller
NPI 1902073216
$11,671.46
in general payments reported to CMS, 2019-2025
31 companies · $3,633 in 2025
The $3,633 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $208 · 2021: $597 · 2022: $1,321 · 2023: $2,297 · 2024: $3,484 · 2025: $3,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,145 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,145.29 |
| Education | $269.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,642.64 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,512.36 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $1,497.28 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,384.07 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,349.33 | 2021-2024 | |
| Axsome Therapeutics, INC. | $937.17 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $475.61 | 2021-2025 | Spravato, Invega Sustenna |
| Braeburn INC. | $406.76 | 2024-2025 | Brixadi |
| Neurocrine Biosciences, INC. | $395.82 | 2021-2025 | Ingrezza |
| Indivior INC. | $269.43 | 2020-2025 | Perseris, Sublocade |
| Supernus Pharmaceuticals, INC. | $244.16 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $207.34 | 2020-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $179.31 | 2022-2025 | Trintellix |
| Eisai INC. | $177.85 | 2021-2024 | |
| Tris Pharma INC | $172.56 | 2025 | Dyanavel Xr, Onyda Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $152.31 | 2022-2025 | Azstarys |
| Allergan, INC. | $133.85 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $101.05 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $76.33 | 2022-2024 | Xelstrym |
| Neuronetics, INC. | $67.58 | 2023 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $58.06 | 2024 | |
| Sunovion Pharmaceuticals INC. | $53.92 | 2019 | |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Sage Therapeutics, LLC | $30.93 | 2024 | |
| Almatica Pharma LLC | $28.24 | 2024-2025 | Loreev Xr |
| Harmony Biosciences LLC | $17.13 | 2025 | |
| Collegium Pharmaceutical, INC. | $15.52 | 2025 | Jornay Pm |
| Lundbeck LLC | $15.17 | 2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $13.17 | 2022 | |
| Idorsia Pharmaceuticals US INC | $11.65 | 2022 | |
| Life Molecular Imaging Ltd | $9.86 | 2024 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.